Clinical trials often focus on the efficacy of biologic agents in the treatment of psoriasis without emphasis on the speed of response.
Objective:
We evaluated clinical trial data to determine which biologic agents achieve the fastest treatment response.
Methods:
A review of phase III clinical trials of biologic agents in psoriasis was performed. Speed was determined by analyzing Psoriasis Area and Severity Index (PASI) 75/90 responder curves to estimate the point at which 50% of subjects achieved that outcome, PASI 75/9050. Time to achieve PASI 75/9050 was averaged across trials.
Results:
Time to achieve PASI 7550, in weeks: brodalumab 210 mg, 3.5; ixekizumab 80 mg Q2 W, 4; secukinumab 300 mg, 5; infliximab 5mg/kg, 5.5; risankizumab 150 mg, 6; guselkumab 100 mg, 6.25; adalimumab 40 mg, 7.25; ustekinumab 45/90 mg, 7.4; certolizumab 400 mg, 7.5; tildrakizumab 100 mg, 9; etanercept 50 mg, 12.5. PASI 9050 responder rate estimations revealed a similar trend.
Conclusion:
Interleukin-17 inhibitors have a more rapid treatment response compared with other classes. Although speed is important, efficacy, persistence, side effects, cost of treatment, and number of injections are all factors to consider.
RitchlinCTKruegerJG. New therapies for psoriasis and psoriatic arthritis. Curr Opin Rheumatol. 2016;28(3):204–210. doi:10.1097/BOR.0000000000000274
2.
KimHJLebwohlMG. Biologics and psoriasis: the beat goes on. Dermatol Clin. 2019;37(1):29–36. doi:10.1016/j.det.2018.07.004
3.
GottliebABBlauveltAThaçiD, et al.Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79(2):302–314.e6. doi:10.1016/j.jaad.2018.04.012
4.
MachadoATorresT. Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. Psoriasis (Auckl). 2018;8:83–92.
5.
ReichKArmstrongAWLangleyRG, et al.Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839. doi:10.1016/S0140-6736(19)31773-8
6.
WarrenRBGooderhamMBurgeR, et al.Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138–1149. doi:10.1016/j.jaad.2019.12.038
7.
SawyerLMalottkiKSabry-GrantC, et al.Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS One. 2019;14(8): e0220868.
8.
PappKALebwohlMG. Onset of action of biologics in patients with moderate-to-severe psoriasis. J Drugs Dermatology. 2018;17(3):247–250.
9.
TorbicaAFattoreGAyalaF.Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics. 2014;32(2):209–223. doi:10.1007/s40273-013-0126-6
10.
ReichKPinterALacourJP, et al.Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014–1023. doi:10.1111/bjd.15666
11.
ArmstrongAWParsiKSchuppCWMeasePJDuffinKC. Standardizing training for psoriasis measures. JAMA Dermatology. 2013;149(5):577–582. doi:10.1001/jamadermatol.2013.1083
12.
SpulsPILecluseLLAPoulsenMLNFBosJDSternRSNijstenT.How good are clinical severity and outcome measures for psoriasis: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933–943. doi:10.1038/jid.2009.391
13.
SampognaFAbeniD. Outcomes in psoriasis clinical trials from January 2011 to March 2012. Curr Dermatol Rep. 2012;1(3):137–147.
14.
LightJGHaidariWFeldmanSR. Assessing efficacy and the speed of response in psoriasis treatment. J Dermatolog Treat. 2019;30(6):523–524. doi:10.1080/09546634.2019.1643588
15.
NastASporbeckBRosumeckS, et al.Which antipsoriatic drug has the fastest onset of action?—Systematic review on the rapidity of the onset of action. J Invest Dermatol. 2013;133(8):1963–1970. doi:10.1038/jid.2013.78
16.
BlauveltAPappKALebwohlMG, et al.Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017;77(2):372–374. doi:10.1016/j.jaad.2017.03.026
17.
WarrenRBSeeKBurgeR, et al.Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses. Dermatol Ther (Heidelb). 2020;10(1):73–86. doi:10.1007/s13555-019-00337-y
18.
ReichKPappKABlauveltA, et al.Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288. doi:10.1016/S0140-6736(17)31279-5
19.
BlauveltAPappKAGriffithsCEM, et al.Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator. J Am Acad Dermatol. 2017;76(3):405–417. doi:10.1016/j.jaad.2016.11.041
20.
ReichKArmstrongAWFoleyP, et al.Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. doi:10.1016/j.jaad.2016.11.042
21.
LebwohlMStroberBMenterA, et al.Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi:10.1056/NEJMoa1503824
22.
LangleyRGElewskiBELebwohlM, et al.Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
23.
GriffithsCEMReichKLebwohlM, et al.Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551. doi:10.1016/S0140-6736(15)60125-8
24.
BarkerJHoffmannMWozelG, et al.Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol.2011;165(5):1109–1117. doi:10.1111/j.1365-2133.2011.10615.x
25.
LangleyRGPappKGooderhamM, et al.Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). Br J Dermatol. 2018;178(6):1315–1323. doi:10.1111/bjd.16426
26.
GordonKBStroberBLebwohlM, et al.Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi:10.1016/S0140-6736(18)31713-6
27.
ThaçiDBlauveltAReichK, et al.Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409. doi:10.1016/j.jaad.2015.05.013
28.
PappKAReidCFoleyP, et al.Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132(10):2466–2469. doi:10.1038/jid.2012.163
29.
PappKALangleyRGSigurgeirssonB, et al.Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–421. doi:10.1111/bjd.12110
30.
McInnesIBSieperJBraunJ, et al.Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase ii proof-of-concept trial. Ann Rheum Dis. 2014;73(2):349–356. doi:10.1136/annrheumdis-2012-202646
31.
LeonardiCMathesonRZachariaeC, et al.Anti–interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–1199. doi:10.1056/nejmoa1109997
32.
PatelDDLeeDMKolbingerFAntoniC. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2): ii116–123. doi:10.1136/annrheumdis-2012-202371
33.
GaffenSL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556–567. doi:10.1038/nri2586
34.
JohnstonAFritzYDawesSM, et al.Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252–2262. doi:10.4049/jimmunol.1201505
35.
PaulC. Ixekizumab or secukinumab in psoriasis: what difference does it make?Br J Dermatol. 2018;178(5):1003–1005. doi:10.1111/bjd.16497
36.
PuigL. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatology Venereol. 2015;29(4):645–648. doi:10.1111/jdv.12817
37.
FlorekAGWangCJArmstrongAW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271–319. doi:10.1007/s00403-018-1808-x
38.
StrohalRPrinzJCGirolomoniGNastA. A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus. J Eur Acad Dermatology Venereol. 2015;29(12):2390–2398. doi:10.1111/jdv.13248
39.
KieslerDJAuerbachSM. Optimal matches of patient preferences for information, decision-making and interpersonal behavior: evidence, models and interventions. Patient Educ Couns. 2006;61(3):319–341. doi:10.1016/j.pec.2005.08.002
40.
UmarNLitakerDSchaarschmidtMLPeitschWKSchmiederATerrisDD. Outcomes associated with matching patients’ treatment preferences to physicians’ recommendations: study methodology. BMC Health Serv Res. 2012;12:1. doi:10.1186/1472-6963-12-1
